ID   Ishikawa
AC   CVCL_2529
SY   ISHIKAWA; ISHI
DR   BTO; BTO_0003041
DR   CLO; CLO_0037163
DR   EFO; EFO_0005718
DR   ArrayExpress; E-MTAB-3610
DR   BCRJ; 0364
DR   BioSample; SAMN03471030
DR   cancercelllines; CVCL_2529
DR   CCRID; 1101HUM-PUMC000686
DR   Cell_Model_Passport; SIDM00038
DR   ChEMBL-Cells; CHEMBL3307675
DR   ChEMBL-Targets; CHEMBL614649
DR   CLS; 305262
DR   Cosmic; 713475
DR   Cosmic; 713499
DR   Cosmic; 809129
DR   Cosmic; 846174
DR   Cosmic; 1070811
DR   Cosmic; 1152553
DR   Cosmic; 1176597
DR   Cosmic; 1177618
DR   Cosmic; 1241344
DR   Cosmic; 1622902
DR   Cosmic; 1696753
DR   Cosmic; 2030475
DR   Cosmic; 2464666
DR   Cosmic; 2646616
DR   Cosmic; 2702440
DR   ECACC; 99040201
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS228AAA
DR   ENCODE; ENCBS229AAA
DR   ENCODE; ENCBS230AAA
DR   GEO; GSM374972
DR   GEO; GSM375431
DR   GEO; GSM827370
DR   GEO; GSM1008593
DR   GEO; GSM1008594
DR   GEO; GSM1669941
DR   GEO; GSM3161714
DR   GEO; GSM3161715
DR   GEO; GSM6421758
DR   GEO; GSM6421759
DR   GEO; GSM6421760
DR   GEO; GSM6421769
DR   GEO; GSM6421770
DR   GEO; GSM6421771
DR   GEO; GSM6421772
DR   GEO; GSM6421773
DR   GEO; GSM6421774
DR   GEO; GSM6421775
DR   GEO; GSM6421776
DR   GEO; GSM6727286
DR   GEO; GSM6727287
DR   IARC_TP53; 1112
DR   LINCS_HMS; 50018
DR   LINCS_LDP; LCL-1497
DR   PharmacoDB; Ishikawa_667_2019
DR   Progenetix; CVCL_2529
DR   PubChem_Cell_line; CVCL_2529
DR   TOKU-E; 3966
DR   Ubigene; YC-D023
DR   Wikidata; Q54898281
RX   DOI=10.1007/978-4-431-53981-0_2;
RX   PubMed=4031568;
RX   PubMed=10381137;
RX   PubMed=12703541;
RX   PubMed=15053063;
RX   PubMed=15901131;
RX   PubMed=20215515;
RX   PubMed=20218740;
RX   PubMed=20944090;
RX   PubMed=22710073;
RX   PubMed=23255909;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=36396974;
WW   Info; ENCODE; -; http://genome.ucsc.edu/ENCODE/protocols/cell/human/Ishikawa_Crawford_protocol.pdf
CC   Part of: ENCODE project common cell types; tier 3.
CC   Population: Japanese.
CC   Doubling time: 36 hours (Note=At 9th passage), 29 hours (Note=At 40th passage), 27 hours (Note=At 50th passage) (DOI=10.1007/978-4-431-53981-0_2); 35.14 +- 2.68 hours (PubMed=23255909).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
CC   Sequence variation: Mutation; HGNC; HGNC:9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Ser302fs*4 (c.906delC); Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=20944090).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=15901131).
CC   Omics: Genomics; ChIP-seq; H3K27ac.
CC   Omics: Genomics; Chromatin accessibility; ATAC-seq.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; SNP array analysis.
CC   Misspelling: Ischikawaa; Note=Occasionally.
CC   Discontinued: CLS; 305262; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): ECACC=99040201; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 9,12
ST   D16S539: 9
ST   D18S51: 13,19
ST   D19S433: 12.2,14
ST   D21S11: 28
ST   D2S1338: 20
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 9,10
ST   D8S1179: 12,16
ST   FGA: 21
ST   Penta D: 10,11
ST   Penta E: 11,19
ST   TH01: 9,10
ST   TPOX: 8
ST   vWA: 14,17
DI   NCIt; C40145; Type I endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 38
CH   CVCL_W441 ! EIIL
CH   CVCL_N296 ! IK-6
CH   CVCL_9996 ! IK-90
CH   CVCL_IR24 ! ISH/DDP
CH   CVCL_6543 ! Ishikawa (Heraklio) 02 ER-
CH   CVCL_8783 ! Ishikawa (London) 02 ER+
CH   CVCL_W420 ! Ishikawa 1-A-12
CH   CVCL_W421 ! Ishikawa 1-A-9
CH   CVCL_W422 ! Ishikawa 1-C-10
CH   CVCL_W423 ! Ishikawa 1-D-9
CH   CVCL_W424 ! Ishikawa 1-E-8
CH   CVCL_W425 ! Ishikawa 1-F-6
CH   CVCL_W426 ! Ishikawa 1-H-6
CH   CVCL_W427 ! Ishikawa 2-B-12
CH   CVCL_W428 ! Ishikawa 2-C-3
CH   CVCL_W429 ! Ishikawa 2-C-7
CH   CVCL_W430 ! Ishikawa 2-E-7
CH   CVCL_W431 ! Ishikawa 2-F-4
CH   CVCL_W432 ! Ishikawa 3-D-7
CH   CVCL_W433 ! Ishikawa 3-D-9
CH   CVCL_D199 ! Ishikawa 3-H-12
CH   CVCL_W434 ! Ishikawa 3-H-3
CH   CVCL_W435 ! Ishikawa 3-H-4
CH   CVCL_W436 ! Ishikawa 3-H-7
CH   CVCL_C9CC ! ISHIKAWA-Luc
CH   CVCL_IJ14 ! Ishikawa-RP
//
RX   PubMed=36396974; DOI=10.1038/s41598-022-24211-8; PMCID=PMC9672046;
RA   Rush, Craig M.
RA   Blanchard, Zannel
RA   Polaski, Jacob T.
RA   Osborne, Kyle S.
RA   Osby, Krystle
RA   Vahrenkamp, Jeffery M.
RA   Yang, Chieh-Hsiang
RA   Lum, David H.
RA   Hagan, Christy R.
RA   Leslie, Kimberly K.
RA   Pufall, Miles A.
RA   Thiel, Kristina W.
RA   Gertz, Jason
RT   "Characterization of HCI-EC-23 a novel estrogen- and
RT   progesterone-responsive endometrial cancer cell line.";
RL   Sci. Rep. 12:19731.1-19731.17(2022).
//
RX   PubMed=4031568;
RA   Nishida, Masato
RA   Kasahara, Kunitake
RA   Kaneko, Minoru
RA   Iwasaki, Hirokazu
RA   Hayashi, Kazuo
RT   "Establishment of a new human endometrial adenocarcinoma cell line,
RT   Ishikawa cells, containing estrogen and progesterone receptors.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 37:1103-1111(1985).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg, S. Michael
RA   Mohapatra, Gayatry
RA   Rivera, Miguel N.
RA   Winokur, Daniel
RA   Greninger, Patricia
RA   Nitta, Mai
RA   Sadow, Peter M.
RA   Sooriyakumar, Gaya
RA   Brannigan, Brian W.
RA   Ulman, Matthew J.
RA   Perera, Rushika M.
RA   Wang, Rui
RA   Tam, Angela
RA   Ma, Xiao-Jun
RA   Erlander, Mark
RA   Sgroi, Dennis C.
RA   Rocco, James W.
RA   Lingen, Mark W.
RA   Cohen, Ezra E.W.
RA   Louis, David Neil
RA   Settleman, Jeffrey
RA   Haber, Daniel Arie
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes, Konstantin J.
RA   Wetterskog, Daniel
RA   Mendes-Pereira, Ana M.
RA   Natrajan, Rachael
RA   Lambros, Maryou B.
RA   Geyer, Felipe Correa
RA   Vatcheva, Radost
RA   Savage, Kay
RA   Mackay, Alan
RA   Lord, Christopher J.
RA   Ashworth, Alan
RA   Reis-Filho, Jorge Sergio
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch, Christopher T.
RA   Spillman, Monique A.
RA   Jackson, Twila A.
RA   Jacobsen, Britta M.
RA   Murphy, Susan K.
RA   Lessey, Bruce Arthur
RA   Jordan, Virgil Craig
RA   Bradford, Andrew Peter
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai, Yoshihiro
RA   Hayashi, Shinichi
RA   Takahashi, Hiroyuki
RA   Tsuneyama, Koichi
RA   Takano, Yasuo
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=15053063;
RA   Kamata, Yuko
RA   Watanabe, Junichi
RA   Hata, Hiroki
RA   Hamano, Mieko
RA   Kuramoto, Hiroyuki
RT   "Quantitative study on the correlation between p53 gene mutation and
RT   its expression in endometrial carcinoma cell lines.";
RL   Eur. J. Gynaecol. Oncol. 25:55-60(2004).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio, Francesco
RA   Knijnenburg, Theo A.
RA   Vis, Daniel J.
RA   Bignell, Graham Robert
RA   Menden, Michael Patrick
RA   Schubert, Michael
RA   Aben, Nanne
RA   Goncalves, Emanuel
RA   Barthorpe, Syd
RA   Lightfoot, Howard
RA   Cokelaer, Thomas
RA   Greninger, Patricia
RA   van Dyk, Ewald
RA   Chang, Han
RA   de Silva, Heshani
RA   Heyn, Holger
RA   Deng, Xian-Ming
RA   Egan, Regina K.
RA   Liu, Qing-Song
RA   Mironenko, Tatiana
RA   Mitropoulos, Xeni
RA   Richardson, Laura
RA   Wang, Jin-Hua
RA   Zhang, Ting-Hu
RA   Moran, Sebastian
RA   Sayols, Sergi
RA   Soleimani, Maryam
RA   Tamborero, David
RA   Lopez-Bigas, Nuria
RA   Ross-Macdonald, Petra
RA   Esteller, Manel
RA   Gray, Nathanael S.
RA   Haber, Daniel Arie
RA   Stratton, Michael Rudolf
RA   Benes, Cyril Henri
RA   Wessels, Lodewyk F.A.
RA   Saez-Rodriguez, Julio
RA   McDermott, Ultan
RA   Garnett, Mathew J.
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=12703541; DOI=10.1111/j.1749-0774.2002.tb00105.x;
RA   Nishida, Masato
RT   "The Ishikawa cells from birth to the present.";
RL   Hum. Cell 15:104-117(2002).
//
RX   PubMed=23255909; DOI=10.3892/ol.2012.975; PMCID=PMC3525505;
RA   Zhao, Shun-Jun
RA   Li, Gen-Xia
RA   Yang, Li
RA   Li, Lei
RA   Li, Hong-Yu
RT   "Response-specific progestin resistance in a newly characterized
RT   Ishikawa human endometrial cancer subcell line resulting from
RT   long-term exposure to medroxyprogesterone acetate.";
RL   Oncol. Lett. 5:139-144(2013).
//
RX   PubMed=10381137; DOI=10.1016/S0304-3835(98)00270-5;
RA   Ohta, Hiroho
RA   Sakamoto, Hideki
RA   Satoh, Kazuo
RT   "In vitro effects of gonadotropin-releasing hormone (GnRH) analogue on
RT   cancer cell sensitivity to cis-platinum.";
RL   Cancer Lett. 134:111-118(1998).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu, Ma-Mie
RA   Selvaraj, Suresh K.
RA   Liang-Chu, May M.Y.
RA   Aghajani, Sahar
RA   Busse, Matthew
RA   Yuan, Jean
RA   Lee, Genee
RA   Peale, Franklin V.
RA   Klijn, Christiaan
RA   Bourgon, Richard
RA   Kaminker, Joshua S.
RA   Neve, Richard M.
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   DOI=10.1007/978-4-431-53981-0_2;
RA   Nishida, Masato
RT   "Ishikawa cells: opening of in vitro hormone research on endometrial
RT   carcinoma.";
RL   (In book chapter) Cell and molecular biology of endometrial carcinoma; Kuramoto, Hiroyuki & Nishida, Masato (eds.); pp.35-58; Springer; Tokyo; Japan (2003).
//
RX   PubMed=20218740; DOI=10.1177/153303461000900207; PMCID=PMC5120669;
RA   Wang, Ying-Mei
RA   Yang, Da
RA   Cogdell, David
RA   Hu, Li-Mei
RA   Xue, Feng-Xia
RA   Broaddus, Russell
RA   Zhang, Wei
RT   "Genomic characterization of gene copy-number aberrations in
RT   endometrial carcinoma cell lines derived from endometrioid-type
RT   endometrial adenocarcinoma.";
RL   Technol. Cancer Res. Treat. 9:179-189(2010).
//